Dr John Stageman
Appointed December 2008
Dr Stageman was responsible for developing
AstraZeneca’s competitive biopharmaceutical strategy, leading to
the acquisition of Cambridge Antibody Technology and of MedImmune.
After a period in a transitional role as General Manager of
Cambridge, John has recently returned to the North West as Vice
President of UK Science Affairs. He has been a member of the North
West Science Council since its inception in 2002, and a member of
the Biotechnology and Biological Sciences Research Council since
May 2008, and is an Honorary Professor in Life Sciences at the
University of Manchester.
He holds no other ministerial appointments.
Board sub-committee involvement:
- Member of the Renumeration & Appointments Committee
- Member of the Audit Committee
- Member of the Enterprise Sub-committee
- Member of the Skills & Employment Sub-committee
- Member of the Equality and Economic Inclusion
Sub-committee
- Member of the European Sub-committee
Register of Interests - updated 17th June
2010
| Company Name |
Nature of Interest |
Direct or Indirect Interest |
| Astra Zeneca |
Employee |
Direct |
| Biotechnology & Biological Sciences Research
Council |
Council Member |
Direct |
| Daresbury Executive Steering Group |
Advisor |
Direct |
| Healthtech & Medicines Knowledge Transfer Network for
TSB |
Chairman of Steering Board |
Direct |
| Manchester Premier Fund (managed by MTI) |
Member of Advisory Board |
Direct |
| MIMIT |
Chairman of Board |
Indirect |
| North West Equity Fund |
AZ Ltd Partner Representative |
Direct |
| Wellcome Trust Clinical Research Facility Manchester |
Chairman of Board |
Direct |